Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)

Leukemia

Volumn 22, Issue 10, 2008, Pages 1956-1961

  Preuner, S ^a   Denk, D ^a   Frommlet, F ^b   Nesslboeck, M ^a   Lion, T ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL CLONING; CHRONIC MYELOID LEUKEMIA; CROSS REACTION; DRUG RESPONSE; DRUG SENSITIVITY; GENE SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIGATION DEPENDENT POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION;

EID: 54049143861     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.97     Document Type: Article

References (14)

1. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: The new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-848.
2. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350.
3. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
4. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
5. Soverini S, Gnani A, Colarossi S, Castagnetti F, Palandri F, Giannoulia P et al. Philadelphia chromosome-positive leukemia patients who harbour imatinib-resistant mutations have a higher likelihood of developing additional mutations associated with resistance to novel tyrosine kinase inhibitors. Blood 2007; 110 abstract [322].
6. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100-4109.
7. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
8. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
9. Khorashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 658-663.
10. Vivante A, Amariglio N, Koren-Michowitz M, Ashur-Fabian O, Nagler A, Rechavi G et al. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia 2007; 21: 1318-1321.
11. Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J et al. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene 2008; 27: 775-782.
12. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: E57.
13. Lundberg E, De Mare J. Interval estimates in the spectroscopy calibration problem. Scand J Statistics 1980; 7: 40-42.
14. Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006; 125: 93-106.